#ASCO14 - Poster: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data

CHICAGO, IL USA (UroToday.com) - Presented by Emmanuel S. Antonarakis, Adam Stuart Kibel, George W. Adams, Lawrence Ivan Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Robert Claude Tyler, Candice McCoy, Todd DeVries, Nadeem A. Sheikh, and Charles G. Drake at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 antonarakis thumb

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD USA; Brigham and Women’s Hospital, Harvard University, Urologic Surgery, Boston, MA USA; Urology Centers of Alabama, Homewood, AL USA; The Urology Center of Colorado, Denver, CO USA; Brigham and Women's Hospital/Harvard University, Boston, MA USA; Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC USA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV USA; Virginia Mason Medical Center, Seattle, WA USA; Dendreon Corporation, Seattle, WA USA